ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of $3.16M rose 7.6% year over year, ahead of the -12.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +79.7% a year.

Context

  • Depreciation & amortization amounted to 1.1% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +7.6% holds above the trailing-twelve-month pace of -12.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.16M+5.5% QoQ
Last fiscal yearDec 2025
$11.76M-26.0% YoY
LTMJun 2026
$12.02M-12.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year-26.0%——
3-year CAGR+79.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
11.76M USD
Year-over-year change
-26.0%
4-year CAGR
+36.9%

Depreciation & Amortization vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Jun 2026 depreciation & amortization of $12.02M is the largest of the 11 companies compared; the peer median is $451K.
  • Its year-over-year change of -12.0% is the 6th highest of 9, against a peer median of +8.6%.
  • Depreciation & amortization amounts to 1.1% of revenue for ACAD, versus a peer median of 4.0%.
ACAD Competitors Peer median
Depreciation & Amortization for ACAD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$12.02M -12.0%+79.7%1.1%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$9.94M +16.8%+27.2%1.3%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$8.66M +9.7%—4.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1M +7.4%+296.1%5.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026$674K +14.4%+24.6%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$574K -20.3%+0.2%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K +19.3%-0.6%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$325.5K —+443.4%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$133K -16.4%-30.6%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$59K -90.6%-29.5%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 ———
Peer median (excluding ACAD) $451K+8.6%+12.4%4.0%

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
Deferred Income Tax0000(249.88M)
Stock-Based Compensation63.62M68.2M66.42M67.05M0
Change in Working Capital(24.82M)37.99M18.13M4.16M(89.76M)
Accounts Receivables(16.12M)2.26M(39.27M)(2.35M)(43.54M)
Inventory(4.21M)2.42M(28.81M)(49.55M)(18.2M)
Accounts Payables(1.62M)5.87M4.8M(1.35M)(5.29M)
Other Working Capital(2.88M)27.44M81.41M57.4M(22.73M)
Other Non-Cash Items75K(6.28M)(12.12M)(155.82M)46.71M
Operating Cash Flow(125.66M)(114.04M)16.7M157.72M109.84M
Capital Expenditures(1.12M)0(40.05M)(523K)(4.69M)
Acquisitions (Net)69.98M0(32.05M)00
Purchases of Investments(492.8M)(363.17M)(369.99M)(505.1M)(692.57M)
Sales of Investments422.82M436.42M442.03M328.57M493.53M
Other Investing Activities(69.98M)032.05M146.52M0
Investing Cash Flow(71.1M)73.24M32M(30.54M)(302.56M)
Debt Repayment00000
Common Stock Issued18.16M8.2M25.13M6.85M49.88M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow18.16M8.2M25.13M6.85M49.88M
Effect of Forex Changes7K6K(18K)(94K)951K
Net Change in Cash(178.59M)(32.59M)73.81M133.93M(141.89M)
Free Cash Flow(126.78M)(114.04M)(23.35M)157.2M105.15M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.